Target therapy for high grade glioma by using specific antibody against glioma stem cell

• Project/Area Number: 26462187
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurosurgery
• Research Institution: Sapporo Medical University
• Principal Investigator: Wanibuchi Masahiko 札幌医科大学, 医学部, 准教授 (30343388)
• Co-Investigator(Kenkyū-buntansha): 山口 美樹 札幌医科大学, 医学部, 助教 (10530454) ; 鳥越 俊彦 札幌医科大学, 医学部, 教授 (20301400) ; 佐々木 祐典 札幌医科大学, 医学部, 講師 (20538136) ; 三國 信啓 札幌医科大学, 医学部, 教授 (60314217) ; 大瀧 隼也 札幌医科大学, 医学部, 研究員 (20724082) ; 能代 将平 札幌医科大学, 医学部, 研究員 (90749425)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000); Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: 脳腫瘍 / 神経膠腫 / 膠芽腫 / ACTC1 / IL13R alpha 2 / 予後 / 浸潤 / 細胞骨格 / 分子標的

Outline of Final Research Achievements

Target molecules for therapy of gliomas were identified in our study. Actin, alpha cardiac muscle 1 (ACTC1) which was a part of cytoskeletons became a marker of poor prognosis of gliomas. In glioblastoma which median survival was only one year, the difference of overall survival was over two years by presence or absence of ACTC1.ACTC1 was also related to the tumor invasion in high grade gliomas. These results were presented on Journal of Neurosurgery 2017 which was one on top journals in the field of neurosurgery. In addition, interleukin 13 receptor alpha 2 was also related to the poor prognosis in high grade gliomas. This identification will be on Journal of Neurosurgical Sciences in 2017.

Research Products

• [Int'l Joint Research] Yale University School of Medicine(米国)
• [Int'l Joint Research] Yale University(米国)
• [Journal Article] Interleukin-13 receptor alpha 2 as a marker of poorer prognosis in high-grade astrocytomas. (2017)
  • Author(s): Wanibuchi M, Kataoka-Sasaki Y, Sasaki M, Oka S, Otsuka Y, Yamaguchi M, Ohnishi H, Ohtaki S, Noshiro S, Ookawa S, Mikami T, Mikuni N, Honmou O
  • Journal Title: J Neurosurg Sci. Volume: 印刷中 Issue: 3
  • DOI: 10.23736/s0390-5616.16.03793-0
  • Peer Reviewed / Int'l Joint Research / Acknowledgement Compliant
• [Journal Article] ACTC1 as an invasion and prognosis marker in glioma. (2017)
  • Author(s): Ohtaki S, Wanibuchi M, Kataoka-Sasaki Y, Sasaki M, Oka S, Noshiro S, Akiyama Y, Mikami T, Mikuni N, Kocsis JD, Honmou O
  • Journal Title: J Neurosurg. Volume: 126 Issue: 2 Pages: 467-475
  • DOI: 10.3171/2016.1.jns152075
  • Peer Reviewed / Int'l Joint Research / Acknowledgement Compliant
• [Presentation] 悪性グリオーマの浸潤因子解析 (2016)
  • Author(s): 鰐渕昌彦
  • Organizer: 第21回日本脳腫瘍の外科学会
  • Place of Presentation: 虎ノ門ヒルズフォーラム（東京都港区）
  • Year and Date: 2016-09-09